The central government has signed a contract with Serum Institute of India (SII) for the supply of 11 million doses of Covishield, the Indian variant of the Oxford-AstraZenaca vaccine.
SII has manufactured the vaccine under licence in India. The country will start its mass inoculation programme against Covid-19 on January 16.
Around 3 crore healthcare and frontline workers will be the first in line to receive the shot.
